Skip to content
Business Company News, Medical Health Aged Care

Professor Peter van Wijngaarden to become next Director and CEO of The Florey

The Florey 2 mins read
Incoming Florey Direct Professor Peter van Wijngaarden. Photo credit: Anna Carlile

The Florey Board appoints new Director and CEO  

After an extensive global search, Professor Peter van Wijngaarden has been named as the next Director and CEO of The Florey Institute of Neuroscience and Mental Health. 

Board Chair Mr Martin Adams said Professor van Wijngaarden is an outstanding leader and an experienced clinician researcher who will take The Florey’s work to the world stage. 

“On behalf of the Board, I warmly welcome Peter to The Florey. As the largest brain research centre in the Southern Hemisphere, The Florey is home to remarkably talented people committed to advancing neuroscience and mental health research. Peter is exceptionally well-placed to take The Florey’s impact to the next level.” 

Professor van Wijngaarden said he was looking forward to taking up his new role next month. 

“I am honoured to be joining The Florey as its new Director and excited to be working with scientists who are leading the world in making fundamental discoveries in neuroscience and improving diagnostics and treatments for an impressive range of mental health and brain-related conditions,” Professor van Wijngaarden said.  

“The Florey has an incredible reputation and I look forward to building on that impressive legacy,” he said. 

Mr Adams thanked retiring Director Professor Trevor Kilpatrick for his leadership and commitment to the organisation.  

"Trevor has done an outstanding job leading The Florey through a period of important structural changes which have positioned us to continue to make significant scientific breakthroughs with our partners. I’m confident that Peter will build upon these efforts.”  

Professor Kilpatrick said he was proud to have served The Florey as its sixth Director. 

“I’m delighted that Professor van Wijngaarden has accepted this appointment,” Professor Kilpatrick said.  

“I have known Peter since his return from Cambridge where he undertook research in regenerative neuroscience with my long-term friend and colleague Professor Robin Franklin. 

“Since then, Peter has had a stellar career as a clinician scientist, administrator and entrepreneur. He is ideally placed to lead The Florey in the next phase of its journey as a world-leading neuroscience and mental health-oriented research institute.” 

Peter is Professor of Ophthalmology at the University of Melbourne and has served as Deputy Director at the Centre for Eye Research Australia (CERA). 

His research interests include retinal imaging, artificial intelligence, multiple sclerosis and Alzheimer’s disease. 

 


Key Facts:
  • Professor Peter van Wijngaarden has been selected to lead The Florey from 1 August 2024 

  • Professor van Wijngaarden is currently Deputy Director of the Centre for Eye Research Australia 


About us:

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere.

Find out more about us on our website: www.florey.edu.au


Contact details:

Kathryn Powley, Media and Communications Manager

kathryn.powley@florey.edu.au | 0456 666 271

Media

More from this category

  • Business Company News, Medical Health Aged Care
  • 03/07/2024
  • 10:23
Chapter One Advisors

Entrepreneur and athlete backed start-up UAre seeks $1 Million to revolutionise longevity and well-being

UAre, the innovative longevity business founded by experienced entrepreneurs Marc Pasques, Grant Ellison, and Kendrick Louis, has launched a $1 million seed funding round(post…

  • Contains:
  • Business Company News, Oil Mining Resources
  • 03/07/2024
  • 10:20
Jane Morgan Management

Zenith Minerals Ltd (ASX:ZNC) – Lithium Business Update & 2024 Lithium Forward Program

Perth, Australia – 3rd July 2024 | Zenith Minerals Limited (ASX: ZNC) ("Zenith" or the "Company") is pleased to announce the recommencement of lithium exploration drilling at its 100% owned Split Rocks and Waratah Well lithium projects in Western Australia following an 18-month hiatus. This decision follows a strategic review of the Company's lithium business and positive feedback from potential strategic investors. Details of the key drill targets are covered in-depth by a Company presentation released to the ASX today titled “2024 Lithium Forward Program”. Key Highlights Lithium Strategic Review: Following unsolicited inbound expressions of interest from various strategic investors,…

  • Contains:
  • Medical Health Aged Care
  • 03/07/2024
  • 09:33
Royal Australian College of GPs

RACGP welcomes reforms reducing admin burden on GPs

Australia’s peak GP body has welcomed the Senate passing reforms modernising the process for GPs to document patient consent for bulk billing benefits to be paid to their health provider. Under the old legislation, patients had to physically sign to consent for bulk billing benefits to be paid directly to their GP or other health provider. The Health Insurance Legislation Amendment (Assignment of Medicare Benefits) Bill 2024, which passed today, will enable a digital solution for documenting consent, and streamline the process. Royal Australian College of GPs (RACGP) President Dr Nicole Higgins welcomed the reforms. “I applaud Senators for acting…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.